Drug Discovery for Menopause with Gero and AthenaBIO
athenadao.substack.com · 1,720 words · saved by 1 readers
Pharma’s Blind Spot
Dr. Peter Fedichev is the Co-Founder and CEO of Gero, an AI-driven biotech company focused on drug discovery. In January of 2025, AthenaBIO funded a program to focus on menopause following a fortuitous meeting with Dr. Fedichev at JPM Week the previous year. Since then, Gero inked a $250M deal with Roche’s Chugai and has raised a further $23M, with Dr. Fedichev being named a World Economic Forum tech pioneer. Q: You are a longevity drug discovery biotech. How did you get interested in menopause? Our interest in women’s health, and menopause in particular, actually began as a technical…
saved by
related reading
- Menopause Delayfertilitypreservation.org
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- Gap Mapgap-map.org
- What we wish we knew entering the aging fieldlibrariesforthefuture.bio
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Data Gaps that Bottleneck Aging Biomarker Discovery — Norn Groupnorn.group
- What the Aging Field Needs - Celine Haliouacelinehh.com
- Longevity FAQ - Laura Demingldeming.com
- Amaranth Foundation - Longevity and Neuroscienceamaranth.foundation
- The “Stepping Stone” Approach to Getting Longevity Drugs to Market - proto.lifeproto.life
- Reproductive health needs more hard science, not just more appswritingruxandrabio.com
- A primer on the current state of longevity researchowlposting.com